Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1142470 | 1.00 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL4742113 | 0.87 | NR3C1 (0.51) | NR3C1PGR | |
| SCHEMBL4740125 | 0.85 | NR3C1 (0.49) | NR3C1PGR | |
| SCHEMBL1141822 | 0.82 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL1141826 | 0.82 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL1142508 | 0.81 | NR3C1 (0.49) | NR3C1PGR | |
| SCHEMBL1142511 | 0.81 | NR3C1 (0.49) | NR3C1PGR | |
| SCHEMBL1142457 | 0.80 | NR3C1 (0.51) | NR3C1 | |
| SCHEMBL2452082 | 0.80 | NR3C1 (0.50) | NR3C1 | |
| SCHEMBL1142461 | 0.80 | NR3C1 (0.51) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896424-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | claimed |
| EP-1896424-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | claimed |
| WO-2006138373-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1896424-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138373-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | NR0B1, NR3C1, NFKB2 | NR3C1 2/4885PGR 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.